Risk factors
Pyxis Oncology (PYXS) risk factors
Item 1A of every Pyxis Oncology, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
84 risks, 11 new, 4 dropped, 11 reworded since the prior year. Pyxis Oncology highlights ongoing going-concern doubts, heavy reliance on its lead candidate MICVO, and manufacturing risks tied to China suppliers.
Filed Mar 23, 2026 - FY2024 10-K risk factors
77 risks. Pyxis Oncology is a clinical-stage oncology company facing substantial accumulated deficits, operational losses, and ongoing capital needs. Its pipeline relies on novel therapeutic platforms, including micvotabart pelidotin, APXiMAB, and FACT, alongside extensive clinical and regulatory uncertainties.
Filed Mar 18, 2025